-
Product Insights
NewNet Present Value Model: Fate Therapeutics Inc’s FT-576
Empower your strategies with our Net Present Value Model: Fate Therapeutics Inc's FT-576 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Fate Therapeutics Inc’s FT-819
Empower your strategies with our Net Present Value Model: Fate Therapeutics Inc's FT-819 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FT-825 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FT-825 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FT-825 in Solid Tumor Drug Details: FT-825 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FT-522 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FT-522 in Follicular Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FT-522 in Follicular Lymphoma Drug Details: FT-522 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FT-011 in Systemic Sclerosis (Scleroderma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FT-011 in Systemic Sclerosis (Scleroderma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FT-011 in Systemic Sclerosis (Scleroderma) Drug Details: FT-011 (SHP-627) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FT-819 in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FT-819 in Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FT-819 in Non-Hodgkin Lymphoma Drug Details: FT-819 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FT-819 in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FT-819 in Systemic Lupus Erythematosus report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FT-819 in Systemic Lupus Erythematosus Drug Details: FT-819 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FT-522 in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FT-522 in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FT-522 in Primary Mediastinal B-Cell Lymphoma Drug Details: FT-522...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FT-522 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FT-522 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FT-522 in Diffuse Large B-Cell Lymphoma Drug Details: FT-522...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FT-522 in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FT-522 in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FT-522 in B-Cell Non-Hodgkin Lymphoma Drug Details: FT-522 is under...